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Abstract
Background: This study aimed to understand the role of myeloid cell clusters in uninvolved regional lymph nodes from
early stage non-small cell lung cancer patients.
Methods: Uninvolved regional lymph node sections from 67 patients with stage I–III resected non-small cell lung cancer
were immunostained to detect myeloid clusters, STAT3 activity and occult metastasis. Anthracosis intensity, myeloid cluster
infiltration associated with anthracosis and pSTAT3 level were scored and correlated with patient survival. Multivariate Cox
regression analysis was performed with prognostic variables. Human macrophages were used for in vitro nicotine treatment.
Results: CD68
+ myeloid clusters associated with anthracosis and with an immunosuppressive and metastasis-promoting
phenotype and elevated overall STAT3 activity were observed in uninvolved lymph nodes. In patients with a smoking
history, myeloid cluster score significantly correlated with anthracosis intensity and pSTAT3 level (P,0.01). Nicotine
activated STAT3 in macrophages in long-term culture. CD68
+ myeloid clusters correlated and colocalized with occult
metastasis. Myeloid cluster score was an independent prognostic factor (P=0.049) and was associated with survival by
Kaplan-Maier estimate in patients with a history of smoking (P=0.055). The combination of myeloid cluster score with either
lymph node stage or pSTAT3 level defined two populations with a significant difference in survival (P=0.024 and P=0.004,
respectively).
Conclusions: Myeloid clusters facilitate a pro-metastatic microenvironment in uninvolved regional lymph nodes and
associate with occult metastasis in early stage non-small cell lung cancer. Myeloid cluster score is an independent
prognostic factor for survival in patients with a history of smoking, and may present a novel method to inform therapy
choices in the adjuvant setting. Further validation studies are warranted.
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Introduction
Lung cancer is the most frequent cause of cancer death in the
United States.[1] Despite reduced smoking rates, cigarette smoke
is still the main risk factor associated with lung cancer.[2] Tobacco
smoke contains thousands of chemicals, about 70 of which are
known carcinogens.[3] Anthracosis, which is the deposition of
black dust matter, has been found in the lungs and lymph nodes
(LNs) of those with a history of smoking.[4] Exposure to tobacco
smoke induces mutagenesis leading to the development of lung
cancer, and continued smoking causes increased mortality and
recurrence in early stage disease.[5] Although therapies are
available for the treatment of non-small cell lung cancer (NSCLC),
most patients develop recurrence due to its highly invasive and
metastatic capacity. New strategies are needed for the early
prediction of micrometastatic disease and invasive capacity of
NSCLC.
Within the tumor microenvironment, immune cells produce
immunosuppressive factors, such as interleukin (IL)-6, IL-10,
transforming growth factor-b and vascular endothelial growth
factor (VEGF), resulting in ineffective anti-tumor immune
responses and promotion of tumor growth, angiogenesis and
invasion.[6,7,8,9,10] The microenvironment of malignancies
including NSCLC converts myeloid cells, which are essential for
PLOS ONE | www.plosone.org 1 May 2013 | Volume 8 | Issue 5 | e65121both innate and adaptive immunity, into immunosuppressive cells
that facilitate immune evasion.[6,11,12,13] Constitutive activation
of signal transducer and activator of transcription 3 (STAT3) in
myeloid cells is crucial for the development of immunosuppression
in primary tumors and their microenvironment.[7,9,14]
The importance of myeloid cells has been described in
conditioning pre-metastatic tissue for the future seeding of
metastatic tumor cells.[15,16,17,18,19,20,21,22,23] In some
tumor models, infiltrating myeloid cells in pre-metastatic tissue
form clusters, which are so-called ‘‘pre-metastatic nich-
es.’’[16,19,20] In a recent report, the sphingosine-1-phosphate
receptor 1 (S1PR1)-STAT3 signaling axis in myeloid cells was
shown to be critical for myeloid cell colonization in pre-metastatic
sites, promoting metastasis.[24] The correlation between infiltra-
tion of myeloid cell clusters at pre-metastatic sites and patient
prognosis has not been previously described. We hypothesized that
infiltration of myeloid cells and elevated STAT3 activity within
pre-metastatic tissue from NSCLC patients could predict patient
outcomes following surgical resection. Regional LNs are com-
monly invaded by NSCLC cells in the process of metastasis. We
studied uninvolved regional LNs from patients with resectable
NSCLC to determine the association between myeloid cell
clusters, the activation of STAT3 and patient prognosis.
Materials and Methods
Clinical samples
Patient specimens were collected in accordance with the City of
Hope institutional review board (IRB#10062) and patient written
informed consent was obtained. Uninvolved lymph node tissue
was collected from 67 patients with a pathologically verified
diagnosis of NSCLC who underwent either mediastinal lymph
node sampling or complete lymphadenectomy and were found to
have pathologically determined N0 disease, or N1–N3 disease.
The patients had at least 1 lymph node characterized as
uninvolved with tumor, with available paraffin-embedded tissue.
One uninvolved lymph node tissue block from each qualified
patient was obtained and four-mm sections were prepared for
subsequent analyses. Staging was determined by the American
Joint Committee on Cancer Guidelines, 7
th edition.[25] Patient
demographics and clinical characteristics are presented in Table 1.
Normal LN sections from 4 individuals without cancer were
purchased from Abcam, Imgenex and GeneTex, and all were
ethically obtained and examined and diagnosed by licensed
pathologists.
Immunohistochemistry (IHC)
Sections were incubated with antibodies against CD68 (AbD
Serotec, clone 514H12, 1:50), pY705-STAT3 (Cell Signaling,
clone D3A7, 1:50), CD33 (Leica, clone PWS44, 1:200), CD163
(AbD Serotec, clone EDHu-1, 1:200), IL-6 (Abcam, 1:400), IL-10
(AbD Serotec, clone JES3-12G8, 1:100), VEGF-A (Abcam, clone
VG-1, 1:200), matrix metalloproteinase 9 (MMP-9, Cell Signaling,
1:100), Stromal cell-derived factor 1/Chemokine (C-X-C motif)
ligand 12 (SDF-1/CXCL12, R&D, clone 79018, 1:100), B-cell
lymphoma-extra large (Bcl-xL, Cell Signaling, clone 54H6, 1:200)
or pan-cytokeratin (pan-CK, eBioscience, clone AE1/AE3
[26,27], 1:1000) overnight at 4uC. ABC elite kit and 3,39-
Diaminobenzidine (Vector Labs) were used according to specifi-
cations. Images were captured with Nikon Eclipse TE2000-U
microscope. Quantification was performed with Image Pro Plus.
Immunofluorescence and confocal microscopy
After antigen retrieval, sections were blocked with Image-iT FX
Signal Enhancer (Invitrogen) followed by 10% goat serum, and
incubated with primary antibodies overnight at 4uC. Cellular
fibronectin (cFn) antibody was from Abcam. Slides were then
probed with either fluorophore-labeled secondary antibody or
biotinylated secondary antibody followed by fluorophore-labeled
streptavidin. Images were captured with Zeiss LSM510 upright
confocal microscope.
Scoring method and the detection of occult metastasis
Slides were evaluated under the microscope by two independent
observers (W.Z. and C.Y.) without knowledge of the patients’
clinical details. HE-stained sections were examined throughout
under 100x magnification to score anthracosis intensity on an
integer scale ranging from 1 to3 as follows: 1, small anthracotic
pigment scattered in the cells and appeared cloudy; 2, carbon
pigment appeared solid but scattered (not clustered); 3, clusters of
more than about 50 cells with solid carbon pigment was observed.
Representative images are shown in Fig. 1. For myeloid cluster
infiltration evaluation, IHC slides stained for CD68 were
examined under 40x magnification throughout the entire sections
and scored on an integer scale from 1 to 3 as follows: 1, myeloid
cluster area was smaller than 5% of the whole tissue area; 2,
myeloid cluster area was between 5% and 50% of the whole LN
tissue area; 3, myeloid cluster area was greater than 50% of the
total LN tissue area (Fig. 1). Overall pSTAT3 level was scored as
the percentage of pSTAT3
+ cells in 10 random fields under 100x
magnification (Fig. 1). STAT3 activity in myeloid cells associated
with anthracosis was scored on an integer scale from 1 to 3 in 10
random fields under 200x magnification: 1, less than 5% of the
anthracotic cells were pSTAT3
+; 2, 5%–50% were pSTAT3
+;3 ,
over 50% were pSTAT3
+ (Fig. 1). In case of disagreement
regarding anthracosis intensity, myeloid cluster infiltration and
myeloid cell pSTAT3 level, the sections were re-evaluated by the
two observers together and a final decision was made. In case of
disagreement on overall pSTAT3 level, a mean value was
calculated as the final score.
For prognostic evaluation, patients were dichotomized into low
and high groups for each marker: Anthracosis intensity: 1 or 2=
low, 3= high; myeloid cluster infiltration associated with
anthracosis: 1 or 2= low; 3= high; Overall STAT3 activity: less
than or equal to 50%= low, more than 50%= high; STAT3
activity in myeloid cells associated with anthracosis: 1= low, 2 or
3= high.
Slides stained for pan-CK using IHC were evaluated for the
presence of occult metastasis under 1006 and 2006 magnifica-
tion. Occult metastatic NSCLC cells are relatively large in size,
high in nuclear-cytoplasmic ratio, and show clear and intensive
ring-like cytoplasmic dark brown 3,39-Diaminobenzidine-staining.
[28]
Cell culture
THP-1 was obtained from American Type Culture Collection
and differentiated into macrophages by phorbol 12-myristate 13-
acetate stimulation. Human peripheral blood mononuclear cells
from healthy donors were isolated with Histopaque 1077 (Sigma).
Monocytes were enriched with EsaySep CD14
+ selection kit
(StemCell Technologies) and differentiated into macrophages by
culturing at presence of 10 ng/mL granulocyte-macrophage
colony-stimulating factor (PeproTech) for 6 days and resting for
1 day. Macrophages were treated with nicotine (Sigma-Aldrich)
with or without 1 mM AZD1480 (provided by AstraZeneca), for
the indicated time.
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Demographic or characteristic Smoking group (n=49) Non-smoking group (n=18) P
No. of patients % No. of patients %




Male 22 44.9 2 11.1
Female 27 55.1 16 88.9
Ethnic origin 0.0006
White 46 93.9 10 55.6
Asian 2 4.1 7 38.9
Black 1 2.0 1 5.6




0 22 44.9 12 66.7
1 27 55.1 6 33.3




Squamous cell carcinoma 15 30.6 2 11.1
Adenocarcinoma 30 61.2 16 88.9
Large cell carcinoma 2 4.1 0 0.0
Mixed carcinoma 2 4.1 0 0.0
Pathologic stage
Overall stage 0.49
I 23 46.9 10 55.6
II 12 24.5 2 11.1
III 14 28.6 6 33.3
T stage 0.75
T1 18 36.7 9 50.0
T2 23 46.9 6 33.3
T3 6 12.2 2 11.1
T4 2 4.1 1 5.6
N stage 0.78
N0 28 57.1 12 66.7
N1 11 22.5 3 16.6
N2 10 20.4 3 16.6
Average No. of mediastinal LNs sampled 5.1 4.5 0.24
Pre-surgical therapy received 0.96
None 44 89.8 16 88.9
Chemotherapy 2 4.1 1 5.6
Radiotherapy 0 0.0 0 0.0
Chemoradiotherapy 3 6.1 1 5.6
Post-surgical therapy received 0.41
None 31 63.3 14 77.7
Chemotherapy 3 6.1 2 11.1
Radiotherapy 9 12.2 1 5.6
Chemoradiotherapy 6 18.4 1 5.6
NA, not applicable.
doi:10.1371/journal.pone.0065121.t001
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Equal amounts of cell lysate proteins prepared with RIPA buffer
were subjected to sodium dodecyl sulfate polyacrylamide gel
electrophoresis and immunoblotted with antibodies to pY705-
STAT3 (Cell Signaling), total STAT3 (Santa Cruz) and b-actin
(GE healthcare).
Statistical analysis
Quantified positive staining areas of IHC were analyzed with
Student’s t-test. Pairwise correlations among laboratory biomarker
measurement were assessed by the Spearman’s rank correlation
coefficient. Kaplan-Meier curves were generated to evaluate
differences between survival curves and P-values based on the
log-rank test were presented. Measurements of each biomarker
were fit with a univariate Cox proportional hazards regression
model. To investigate additional prediction power beyond clinical
variables, multivariate Cox regression analysis was also carried out
for model selection among stage, nodal stage, anthracosis intensity,
myeloid clusters associated with anthracosis, overall pSTAT3
level, myeloid cluster pSTAT3 level and occult metastasis. An
effect was considered to be statistically significant when the
corresponding P-value ,0.05 (*, P,0.05; **, P,0.01; ***,
P,0.001). All statistical analyses were performed using the R
software.
Results
Myeloid clusters are prominent and overall STAT3 activity
is dramatically elevated in uninvolved NSCLC regional
lymph nodes
Compared with normal LNs from individuals without cancer,
prominent carbon pigment deposition, i.e. anthracosis, was
observed in uninvolved LNs from NSCLC patients as shown in
Fig. 2A. Immunofluorescent staining demonstrated the anthracotic
cells were CD68
+ myeloid cells (Fig. 2A). Compared to uninvolved
regional LNs from prostate cancer, melanoma or breast cancer
patients (data not shown), the presence of myeloid cells associated
with anthracosis was unique in uninvolved NSCLC regional LNs.
By IHC staining, we found that the myeloid cells associated with
anthracosis usually formed clusters, which was not observed in
normal LNs (Fig. 2B). Elevated overall STAT3 activity in
uninvolved LNs from NSCLC patients was also detected by
IHC staining for pY705-STAT3 (Fig. 2B).
Figure 1. Scoring method. HE staining and IHC staining for CD68 or pSTAT3 showing representative images for the scoring of anthracosis
intensity, anthracotic myeloid cluster infiltration, overall STAT3 activity and anthracotic myeloid cell STAT3 activity. The number on the upper-left
corner of each image shows the score. (Scale bar, 200 mm)
doi:10.1371/journal.pone.0065121.g001
Myeloid Clusters Promote Metastasis in Lung Cancer
PLOS ONE | www.plosone.org 4 May 2013 | Volume 8 | Issue 5 | e65121Positive correlations between anthracosis intensity,
myeloid cluster infiltration and pSTAT3 level in NSCLC
patients with a history of smoking
In patients with a history of smoking, anthracosis intensity,
myeloid clusters associated with anthracosis, overall STAT3
activity and anthracotic myeloid cell STAT3 activity were not
associated with disease progression (data not shown). However,
CD68
+ myeloid cluster infiltration positively correlated with
anthracosis intensity and overall pSTAT3 activity (Fig. 3A).
STAT3 activation in anthracotic myeloid clusters also associated
with anthracosis intensity (Fig. 3A). In contrast, in patients without
a history of smoking, anthracosis was detected but correlations
between STAT3 and anthracosis or myeloid clusters associated
with anthracosis were not found (Fig. 3A). Thus, we focused our
investigation on the role of myeloid clusters and STAT3 in the
patients with a smoking history.
Nicotine activates STAT3 in human macrophages
Tobacco smoking is one of the major causes of anthracosis
within lung tissue.[4,29] Since the correlation between anthracosis
intensity and STAT3 activity was only observed in NSCLC
patients with a history of smoking, we evaluated whether the
addictive component of tobacco smoke, nicotine, activates STAT3
in human macrophages. As shown in Fig. 3B, STAT3 activity was
elevated in both monocytic cell line THP-1-derived macrophages
and primary monocyte-derived macrophages after nicotine
treatment for 2 days, and the activation was completely abrogated
by a Janus kinase (JAK) inhibitor, AZD1480, showing the
activation is via JAK-STAT3 pathway.
Pro-cancer and pro-metastatic phenotype of myeloid
clusters
We characterized the phenotype of CD68
+ myeloid clusters
associated with anthracosis in uninvolved regional LNs from
NSCLC patients with smoking history with IHC (Fig. 4). Since
anthracotic pigment stays on the tissue during immunostaining, it
Figure 2. Prominent myeloid clusters associated with anthracosis and elevated STAT3 activity in NSCLC uninvolved LNs. (A) HE
staining of normal LNs from individuals without cancer (n=4; left two panels) and uninvolved regional LNs from NSCLC patients (middle two panels)
showing anthracotic carbon pigment (indicated with arrows; Scale bar, 20 mm) in patient LNs. Immunofluorescent staining for CD68 (right panel)
demonstrating anthracotic pigment is within CD68
+ cells (Note the black dots indicated with small arrows in CD68
+ cells; Scale bar, 20 mm). (B) IHC
staining showing prominent CD68
+ myeloid clusters associated with anthracosis and highly activated STAT3 in uninvolved NSCLC regional LNs (right
panels) compared to normal LNs (n=4; left panels) (Scale bar, 200 mm).
doi:10.1371/journal.pone.0065121.g002
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anthracosis. The expression of CD33 confirmed these cells were
from myeloid linage (data not shown). To investigate whether the
myeloid clusters were M2-polarized, we performed CD163
staining and the clusters showed strong staining. Investigation of
myeloid cluster phenotype showed expression of IL-6 and IL-10,
which are both immunosuppressive factors. The expression of
VEGF-A and MMP-9 indicated a role in angiogenesis and tissue-
remodeling. VEGF-A is also known to inhibit dendritic cell
maturation.[30] Activation of STAT3 up-regulates Bcl-xL expres-
sion in myeloid cells,[24] and myeloid clusters showed positive
staining for Bcl-xL. SDF-1/CXCL12 has a role in recruiting
NSCLC via the SDF-1/CXCL12-CXC chemokine receptor type
4 axis,[31,32] and IHC staining showed that SDF-1 was highly
expressed by myeloid clusters. All these molecules are STAT3
downstream regulated genes.[7] In addition, IL-6, IL-10 and
VEGF-A are STAT3 activators.[7] Statistical analysis showed a
significant difference in the expression of these molecules between
myeloid clusters associated with anthracosis and other areas within
the LN.
Myeloid clusters correlate and colocalize with LN occult
metastasis
The presence of occult LN metastasis has been linked to poor
prognosis in a large cohort of patients with resectable NSCLC.[28]
By evaluating pan-CK, we detected occult metastatic tumor cells
in the LNs of 8 patients out of the 49 patients with a smoking
history (Fig. 5A). Interestingly, the majority of patients positive for
occult LN metastasis (7 out of 8) showed increased myeloid clusters
associated with anthracosis in the uninvolved LNs (Fig. 5A). The
presence of occult LN metastasis was positively correlated with
myeloid clusters associated with anthracosis (P=0.012, r=0.350)
and anthracosis intensity (P=0.032, r=0.310). In addition, the
occult metastatic tumor cells were usually detected within or very
close to clusters of myeloid cells associated with anthracosis (6 out
of 8; Fig. 5A(a–b)). Double staining for pan-CK and CD68
confirmed the colocalization (Fig. 5B).
Figure 3. Positive correlations between myeloid clusters and STAT3 activity in patients with a smoking history. (A) In patients with a
smoking history, but not in those without a history of smoking, myeloid cluster infiltration associated with anthracosis correlates with anthracosis
intensity and overall STAT3 activity; anthracosis correlates with STAT3 activity in myeloid clusters associated with anthracosis. The correlation was
determined with nonparametric Spearman’s rank correlation test. Shown are means 6 SEM, ** P,0.01, *** P,0.001. (B) Nicotine activates STAT3 in
human macrophages. Western blotting showing pSTAT3 and total STAT3 expression in human THP-1-derived macrophages and human primary
monocyte-derived macrophages after nicotine treatment with or without AZD1480.
doi:10.1371/journal.pone.0065121.g003
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elevated and it plays an important role in the formation of pre-
metastatic myeloid clusters.[16] In addition, STAT3 regulates the
expression of cFn in pre-metastatic myeloid cells.[24] LN sections
stained for cFn and CD68 showed that cFn is colocalized with
small clusters of myeloid cells associated with anthracosis (Fig. 5C),
indicating a possible role of cFn in the recruitment of myeloid cells
and cluster formation in NSCLC regional uninvolved LNs.
Myeloid clusters and overall pSTAT3 level predict the
prognosis of NSCLC patients with a history of smoking
We assessed the prognostic value of anthracosis intensity,
CD68
+ myeloid cluster infiltration associated with anthracosis and
pSTAT3 level. In a univariate analysis, anthracotic myeloid cluster
score showed a trend toward significance in the prediction of
overall survival (P=0.061, Hazard ratio (HR)=2.22, 95% CI
[0.96, 5.13]). A Kaplan-Meier survival estimate with Log-rank test
also demonstrated a near-significant difference between myeloid
cluster associated with anthracosis-high and -low group (P=0.055;
Fig. 6A). Both median survival and 5-year survival are improved in
the low myeloid cluster group (median survival: 116.1 months,
95% CI [86.0, NA] vs. 56.1 months, 95% CI [35.1 - NA]; 5-year
survival: 78.5%, 95% CI [63.3%, 97.3%] vs. 38.0%, 95% CI
[20.8%, 69.3%]). Moreover, overall pSTAT3 showed a trend
toward significance in the prediction of overall survival (P=0.093;
Fig. 6B).
In a multivariate Cox regression analysis for model selection,,
nodal stage and anthracotic myeloid cluster score were left in the
final model (nodal stage: P=0.033, HR=1.75, 95% CI [1.05,
Figure 4. Tumor-promoting phenotype of the myeloid clusters. IHC staining demonstrating the expression of CD163, IL-6, IL-10, VEGF-A,
MMP-9, SDF-1 and Bcl-xL by the myeloid cells associated with anthracosis. For each protein, representative images showing positive and negative
staining areas were selected from the same slide. The quantification was performed by analyzing random images of myeloid cluster areas associated
with anthracosis and other areas (10 images for each group) from 10 patients. Two-tailed Student’s t-test was used for statistical analysis. Shown are
means 6 SEM, *** P,0.001. (Scale bar, 200 mm for 1006and 4006;2 5mm for 16006)
doi:10.1371/journal.pone.0065121.g004
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95% CI [1.00, 5.43]), showing that myeloid clusters associated
with anthracosis in regional uninvolved LNs provide additional
prediction power to patient overall survival beyond conventional
clinicopathological variables. Therefore, we combined nodal stage
and myeloid clusters associated with anthracosis to improve the
overall survival prediction. Despite a limited sample size, patients
with negative LNs and low myeloid clusters demonstrated
significantly improved survival compared to those with positive
LNs and high myeloid clusters (P=0.024; median survival: 113.0
months vs. 44.0 months; 5-year survival: 83.1% vs. 15.0%;
Fig. 6C). The combination of anthracotic myeloid cluster score
and overall pSTAT3 level also defined two populations of patients
with significantly different prognosis (P=0.0041; Fig. 6D). These
data suggest that myeloid clusters associated with anthracosis in
uninvolved LNs are independent predictors of poor prognosis in
smoking NSCLC patients.
Discussion
Development of metastatic disease following surgical resection
of NSCLC requires multifaceted interactions facilitated by tumor
and stromal cells within the microenvironment at the metastatic
site, including immune cells. Infiltration of CD68
+ myeloid cell
clusters associated with anthracosis was prominent in benign LN
from NSCLC patients and activation of STAT3 was elevated,
consistent with earlier reports in multiple malignancies.[14,24]
Pre-metastatic niche formation has been attributed to a variety of
mediators including VEGF, MMP-9, STAT3 and SDF-1/
CXCL12.[16,20,21,24] Phenotypic delineation of the myeloid
clusters seen in uninvolved LN showed expression of IL-6, IL-10
and VEGF-A as inhibitors of antitumor immunity, VEGF-A and
MMP-9 as pro-angiogenic factors and SDF-1 as a chemoattractant
to circulating NSCLC cells. The abundant myeloid clusters
associated with anthracosis in uninvolved LNs may contribute to
the immunosuppressive environment and play a pro-cancer and
Figure 5. Myeloid clusters in uninvolved LNs colocalize with occult metastasis and cFn. (A) IHC staining showing occult metastasis in
‘‘uninvolved’’ LNs (top two panels) and metastatic tumor cells in an involved LN as the positive control (lower left panel) (Scale bar, 50 mm). The bar
graph shows the correlation between myeloid cluster infiltration associated with anthracosis and the presence of occult metastasis (OM). The P value
was determined by nonparametric Spearman’s rank correlation test. (B) Confocal images showing the colocalization of pan-CK
+ NSCLC cells (arrows)
and CD68
+ myeloid clusters associated with anthracosis. (Scale bar, 50 mm) (C) Confocal images showing the colocalization of myeloid clusters
associated with anthracosis (arrows) and cFn. (Scale bar, 50 mm)
doi:10.1371/journal.pone.0065121.g005
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also consistent with a previous report on pre-metastatic myeloid
clusters.[24]
In the tumor microenvironment, STAT3 mediates multidirec-
tional crosstalk between tumor-associated myeloid cells and other
stromal cells, including endothelial cells. [10] Thus, in addition to
the effect of tumor-secreted factors and smoking, the elevation of
STAT3 activity in pre-metastatic LNs may also contribute to
tumor metastasis and progression through the infiltration of
myeloid cells. Recent investigations demonstrate that inhibition of
STAT3, which is constitutively activated in pre-metastatic niches,
can decrease myeloid cell infiltration in future metastatic
sites.[24,33] STAT3 also impairs antitumor immunity to facilitate
carcinogen-induced lung tumor formation.[34] Our data shows
that nicotine was able to activate STAT3 in human macrophages
with subsequent abrogation by JAK/STAT inhibition, suggesting
that formation of pre-metastatic sites and metastases in patients
with smoking-related NSCLC may be sensitive to STAT3
blockade.
Detection of occult metastases in patients with resected NSCLC
provides additional prognostic criteria, which may be used in
determining adjuvant therapy.[28] When we evaluated occult
metastasis in benign LNs, most were found in those with high
levels of myeloid clusters associated with anthracosis and the occult
metastatic tumor cells colocalized within these clusters. Recruit-
ment of these myeloid clusters and subsequent occult metastasis
may be due to cFn, which was also present in uninvolved LN at
the site of the clusters.
Because myeloid cell STAT3 activity not only impacts immune
regulation in the context of tumor,[14] but also plays an important
role in pre-metastatic tissue,[24] the formation of myeloid clusters
and the activation of STAT3 may affect patient prognosis. In
patients without lymph node involvement, those with low levels of
myeloid clusters associated with anthracosis showed improved
survival. The combination of anthracitic myeloid cluster score and
pSTAT3 level further defined prognosis beyond tumor and LN
stage in patients with resectable NSCLC.
Although our findings are promising, the current study has
several limitations. First, the conclusions are limited by the small
number of patients that form our cohort. Future studies with larger
patient numbers will be performed to validate the conclusions.
Second, our previous publication showed that STAT3 activation
in myeloid clusters is crucial for their colonization at pre-
metastatic sites to facilitate metastasis in mouse models. [24]
Likewise, our current study indicates that myeloid cluster
infiltration in uninvolved LNs of NSCLC patients correlates with
occult metastasis and prognosis. However, it is important to note
that the correlation does not equal causation. Myeloid cluster
accumulation in NSCLC pre-metastatic LNs may occur as a
secondary event during metastatic progression. Thus, direct
evidence would be necessary to prove that CD68
+ myeloid
clusters are responsible for priming NSCLC nodal metastasis.
Despite the limitations, our study provides evidence that
STAT3 and myeloid infiltration associate with early metastatic
disease and may be important in smoking-induced lung cancers.
The correlation of myeloid clusters associated with anthracosis and
pSTAT3 with patient survival offers additional information when
Figure 6. Myeloid clusters and pSTAT3 predicts survival in NSCLC patients with a smoking history. Kaplan-Meier curves showing the
survival of patients grouped by: (A) myeloid cluster infiltration associated with anthracosis, (B) overall pSTAT3 level, (C) the combination of nodal
stage and myeloid clusters associated with anthracosis, (D) the combination of myeloid clusters associated with anthracosis and overall pSTAT3 level
(n=49).
doi:10.1371/journal.pone.0065121.g006
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PLOS ONE | www.plosone.org 9 May 2013 | Volume 8 | Issue 5 | e65121considering future therapy. Inhibition of pathways which stimulate
pre-metastatic niche formation may prove more effective than
standard chemotherapy. Investigation in larger cohorts for
validation and prospective trials will further define the role of
myeloid clusters and STAT3 in early stage NSCLC. Furthermore,
examination of fresh tissue and isolation of viable myeloid clusters
will provide insights into the cellular mechanisms involved.
Acknowledgments
We would like to thank Brian Armstrong, Ph.D. of Light Microscopy
Imaging Core, Rebecca Nelson, Ph.D. of Department of Information
Sciences and staff members of Pathology Core at City of Hope
Comprehensive Cancer Center, for their assistance in the study.
Author Contributions
Conceived and designed the experiments: KLR SKP RAF HY. Performed
the experiments: WZ CY KLR SKP. Analyzed the data: WZ XL SA SB
KLR. Contributed reagents/materials/analysis tools: WZ SKP KLR RAF
HY. Wrote the paper: WZ CY SKP SA SB XL RAF HY KLR.
References
1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA
Cancer J Clin 62: 10–29.
2. (2004). The Health Consequences of Smoking: A Report of the Surgeon
General. Atlanta (GA).
3. Hoffmann D, Hoffmann I, El-Bayoumy K (2001) The less harmful cigarette: a
controversial issue. a tribute to Ernst L. Wynder. Chem Res Toxicol 14: 767–
790.
4. Hou M, Morishita Y, Iijima T, Mase K, Dai Y, et al. (1998) The implication of
anthracosis in the development of pulmonary adenocarcinoma. Jpn J Cancer
Res 89: 1251–1256.
5. Parsons A, Daley A, Begh R, Aveyard P (2010) Influence of smoking cessation
after diagnosis of early stage lung cancer on prognosis: systematic review of
observational studies with meta-analysis. BMJ 340: b5569.
6. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V (2012) Coordinated regulation
of myeloid cells by tumours. Nat Rev Immunol 12: 253–268.
7. Yu H, Pardoll D, Jove R (2009) STATs in cancer inflammation and immunity: a
leading role for STAT3. Nat Rev Cancer 9: 798–809.
8. Zou W (2005) Immunosuppressive networks in the tumour environment and
their therapeutic relevance. Nat Rev Cancer 5: 263–274.
9. Yu H, Kortylewski M, Pardoll D (2007) Crosstalk between cancer and immune
cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7: 41–
51.
10. Kujawski M, Kortylewski M, Lee H, Herrmann A, Kay H, et al. (2008) Stat3
mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest 118:
3367–3377.
11. Perrot I, Blanchard D, Freymond N, Isaac S, Guibert B, et al. (2007) Dendritic
cells infiltrating human non-small cell lung cancer are blocked at immature
stage. J Immunol 178: 2763–2769.
12. Fridlender ZG, Kapoor V, Buchlis G, Cheng G, Sun J, et al. (2011) Monocyte
chemoattractant protein-1 blockade inhibits lung cancer tumor growth by
altering macrophage phenotype and activating CD8+ cells. Am J Respir Cell
Mol Biol 44: 230–237.
13. Dumitriu IE, Dunbar DR, Howie SE, Sethi T, Gregory CD (2009) Human
dendritic cells produce TGF-beta 1 under the influence of lung carcinoma cells
and prime the differentiation of CD4+CD25+Foxp3+ regulatory T cells.
J Immunol 182: 2795–2807.
14. Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, et al. (2005) Inhibiting
Stat3 signaling in the hematopoietic system elicits multicomponent antitumor
immunity. Nat Med 11: 1314–1321.
15. Hiratsuka S, Nakamura K, Iwai S, Murakami M, Itoh T, et al. (2002) MMP9
induction by vascular endothelial growth factor receptor-1 is involved in lung-
specific metastasis. Cancer Cell 2: 289–300.
16. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, et al. (2005)
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-
metastatic niche. Nature 438: 820–827.
17. Hiratsuka S, Watanabe A, Aburatani H, Maru Y (2006) Tumour-mediated
upregulation of chemoattractants and recruitment of myeloid cells predeter-
mines lung metastasis. Nat Cell Biol 8: 1369–1375.
18. Hiratsuka S, Watanabe A, Sakurai Y, Akashi-Takamura S, Ishibashi S, et al.
(2008) The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a
pre-metastatic phase. Nat Cell Biol 10: 1349–1355.
19. Erler JT, Bennewith KL, Cox TR, Lang G, Bird D, et al. (2009) Hypoxia-
induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to
form the premetastatic niche. Cancer Cell 15: 35–44.
20. Kim S, Takahashi H, Lin WW, Descargues P, Grivennikov S, et al. (2009)
Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate
metastasis. Nature 457: 102–106.
21. Psaila B, Lyden D (2009) The metastatic niche: adapting the foreign soil. Nat
Rev Cancer 9: 285–293.
22. Kowanetz M, Wu X, Lee J, Tan M, Hagenbeek T, et al. (2010) Granulocyte-
colony stimulating factor promotes lung metastasis through mobilization of
Ly6G+Ly6C+ granulocytes. Proc Natl Acad Sci U S A 107: 21248–21255.
23. Hiratsuka S, Duda DG, Huang Y, Goel S, Sugiyama T, et al. (2011) C-X-C
receptor type 4 promotes metastasis by activating p38 mitogen-activated protein
kinase in myeloid differentiation antigen (Gr-1)-positive cells. Proc Natl Acad
Sci U S A 108: 302–307.
24. Deng J, Liu Y, Lee H, Herrmann A, Zhang W, et al. (2012) S1PR1-STAT3
signaling is crucial for myeloid cell colonization at future metastatic sites. Cancer
Cell 21: 642–654.
25. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, et al. (2007) The
IASLC Lung Cancer Staging Project: proposals for the revision of the TNM
stage groupings in the forthcoming (seventh) edition of the TNM Classification
of malignant tumours. J Thorac Oncol 2: 706–714.
26. Osaki T, Oyama T, Gu CD, Yamashita T, So T, et al. (2002) Prognostic impact
of micrometastatic tumor cells in the lymph nodes and bone marrow of patients
with completely resected stage I non-small-cell lung cancer. J Clin Oncol 20:
2930–2936.
27. Gu CD, Osaki T, Oyama T, Inoue M, Kodate M, et al. (2002) Detection of
micrometastatic tumor cells in pN0 lymph nodes of patients with completely
resected nonsmall cell lung cancer: impact on recurrence and Survival. Ann
Surg 235: 133–139.
28. Rusch VW, Hawes D, Decker PA, Martin SE, Abati A, et al. (2011) Occult
metastases in lymph nodes predict survival in resectable non-small-cell lung
cancer: report of the ACOSOG Z0040 trial. J Clin Oncol 29: 4313–4319.
29. Wang D, Wang J, Li Y, He Z, Zhang Y (2011) The influence of anthracosis and
p16 ink4a gene aberrant methylation on small-sized pulmonary adenocarcino-
ma. Exp Mol Pathol 90: 131–136.
30. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, et al.
(1996) Production of vascular endothelial growth factor by human tumors
inhibits the functional maturation of dendritic cells. Nat Med 2: 1096–1103.
31. Reckamp KL, Figlin RA, Burdick MD, Dubinett SM, Elashoff RM, et al. (2009)
CXCR4 expression on circulating pan-cytokeratin positive cells is associated
with survival in patients with advanced non-small cell lung cancer. BMC Cancer
9: 213.
32. Phillips RJ, Burdick MD, Lutz M, Belperio JA, Keane MP, et al. (2003) The
stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in
non-small cell lung cancer metastases. Am J Respir Crit Care Med 167: 1676–
1686.
33. Kortylewski M, Kujawski M, Herrmann A, Yang C, Wang L, et al. (2009) Toll-
like receptor 9 activation of signal transducer and activator of transcription 3
constrains its agonist-based immunotherapy. Cancer Res 69: 2497–2505.
34. Ihara S, Kida H, Arase H, Tripathi LP, Chen YA, et al. (2012) Inhibitory roles
of signal transducer and activator of transcription 3 in antitumor immunity
during carcinogen-induced lung tumorigenesis. Cancer Res 72: 2990–2999.
Myeloid Clusters Promote Metastasis in Lung Cancer
PLOS ONE | www.plosone.org 10 May 2013 | Volume 8 | Issue 5 | e65121